Stock listing
Vaccinex, Inc.
Selected listing: VCNX · OTC · USD · US
Vaccinex, Inc. (OTC:VCNX), Health Technology. Latest release Jul 8, 2026: Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial…
- Ticker
- OTC:VCNX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
About Vaccinex, Inc.
Vaccinex, Inc. is a public company trading under the ticker VCNX in the American market. Vaccinex focuses on developing innovative therapies for serious diseases, leveraging its proprietary technology platform.
Latest news from Vaccinex, Inc.
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
July 8, 2026
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025